Novartis Sales Growth Guidance: 5% a Year to 2031 as Kesimpta Peak Rises to $8B
Novartis guides to 5% annual sales growth through 2031, down from 5-6%, while raising peak sales for Kesimpta, Scemblix and Leqvio.
Novartis guides to 5% annual sales growth through 2031, down from 5-6%, while raising peak sales for Kesimpta, Scemblix and Leqvio.
FDA has proposed withdrawing approval of Salerno Pharmaceuticals’ FloLipid simvastatin suspension after repeated missing annual reports. Hearing deadline 18 December.
Viatris has closed its $1.65 billion, $36.50-a-share purchase of Pacira BioSciences, adding non-opioid pain drugs Exparel and Zilretta. Deal numbers, strategy and risks explained.
FDA has proposed its first-ever rule declaring an ingredient not excluded from the supplement definition, clearing a path for NAC. What changes, what does not, and when.
UnitedHealthcare and CPESN USA will pay independent pharmacies for testing, chronic care and medication support for Medicaid members in seven states.
The FDA approved Sanofi’s Infilbray (venglustat), the first drug for neurological symptoms of type 3 Gaucher disease, after it beat enzyme therapy in the LEAP2MONO trial.
Pfizer is paying Starna Therapeutics $330 million upfront, with up to $2.3 billion in milestones, for three preclinical in vivo CAR-T programs in autoimmune disease. Terms, science and risks explained.
Merck ended all development of its non-covalent BTK inhibitor nemtabrutinib after a monitoring committee flagged benefit-risk concerns in Phase 3 BELLWAVE-011. The trials, the reasons and what comes next.
Isomorphic Labs raised $5 billion in biotech’s largest private round. Who invested, how the money will be used and why clinical proof is still missing.